CareDx Sells Lab Products Unit to EuroBio Scientific for $170M, Focuses on Core Testing Business
Event summary
- CareDx to divest its Lab Products business to EuroBio Scientific for $170M in cash.
- Transaction expected to close by Q3 2026, pending Swedish regulatory approval.
- CareDx reports Q1 2026 revenue of $118M, up 39% YoY, with Testing Services revenue growing 48% YoY.
- EuroBio Scientific gains exclusive perpetual rights to distribute post-transplant monitoring IVD tests globally, except in North America.
- CareDx to provide transition services to EuroBio Scientific for at least 6 months post-closing.
The big picture
CareDx's divestiture reflects a broader industry trend of precision medicine companies streamlining operations to focus on high-growth, core competencies. The $170M deal underscores the strategic value of specialized diagnostic assets, particularly in the transplant sector. EuroBio Scientific's acquisition aligns with its expansion strategy in IVD diagnostics, while CareDx aims to redeploy capital toward its Precision Diagnostics Solutions model.
What we're watching
- Strategic Alignment
- How CareDx's focus on Precision Medicine Testing Services and Patient and Digital Solutions will impact its long-term growth trajectory.
- Capital Deployment
- Whether CareDx will use proceeds for inorganic investments or shareholder returns, and the potential impact on its financial profile.
- Integration Risk
- The pace at which EuroBio Scientific can integrate and scale CareDx's Lab Products business globally.
Related topics